Inspira Technologies Receives FDA 510(k) Class II Clearance For INSPIRA ART100 Cardiopulmonary Bypass System
Portfolio Pulse from Benzinga Newsdesk
Inspira Technologies has received FDA 510(k) Class II clearance for its INSPIRA™ ART100 Cardiopulmonary Bypass System, marking a significant regulatory milestone for the company.
May 28, 2024 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inspira Technologies has received FDA 510(k) Class II clearance for its INSPIRA™ ART100 Cardiopulmonary Bypass System, which is a significant regulatory milestone for the company.
The FDA 510(k) Class II clearance is a critical regulatory approval that allows Inspira Technologies to market and sell its INSPIRA™ ART100 Cardiopulmonary Bypass System in the United States. This approval is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100